Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Potent and selective COX-2 inhibitors in the Glaxo Wellcome pipeline

May 4, 1999

Celebrex launched in Canada for arthritis

April 30, 1999

Positive results achieved in Alexion's phase I/II study of 5G1.1 in RA

April 27, 1999

Potent and selective COX-2 inhibitors described in recent patent literature by Novartis

April 23, 1999

Malonic acid-based MMP inhibitors with novel binding properties developed at Roche

April 23, 1999

Monsanto responds to press publication of Celebrex adverse events

April 22, 1999

Phytopharm reports preliminary phase IIa results for P-54 in osteoarthritis

April 22, 1999

FDA advisory committee votes in favor of approval for Vioxx

April 21, 1999

FASEB presentation for PD-159879, an MMP inhibitor with potent antiinflammatory activity

April 21, 1999

New COX-2-selective agents from Abbott

April 21, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...